Myo-inositol in the treatment of premenstrual dysphoric disorder
Gianfranco C, Vittorio U, Maurizio N, Gaspare P, Giuseppe B, Nunzio DT
Published in Human Psychopharmacology
Abstract
Randomized controlled trial showing myo-inositol 4g daily significantly improved mood symptoms, depression, and anxiety in premenstrual dysphoric disorder through modulation of neurotransmitter systems.
Methodology
Randomised, double-blind, placebo-controlled trial comparing myo-inositol powder with placebo in women with premenstrual dysphoric disorder over consecutive menstrual cycles, using standardised symptom rating scales.
Key Findings
Myo-inositol produced greater improvement than placebo in mood, depressive and anxiety symptom ratings in women with PMDD, with good tolerability and no notable adverse effects.
Conclusions
Myo-inositol may offer modest symptomatic benefit in premenstrual dysphoric disorder, plausibly via second-messenger effects on serotonergic signalling, but the evidence base is small.
Limitations
Small sample, single centre, short follow-up over a few cycles, subjective self-rated outcomes, and no active comparator such as an SSRI.
Supplements Studied
Myo-inositol reduced symptoms in women with premenstrual dysphoric disorder.
Outcomes Measured
Randomized controlled trial showing myo-inositol 4g daily significantly improved mood symptoms, depression, and anxiety in premenstrual dysphoric disorder through modulation of neurotransmitter systems.
Myo-inositol reduced symptoms in women with premenstrual dysphoric disorder.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.